HIV Infections Clinical Trial
Official title:
A Ph I/IIa Rand Placebo Ctrl, S-Blind Multictr Dose-Esc Study of SC Intermittent Interleukin-7 CYT107 in Chronically HIV-Infected Pts With CD4 T Lymphocyte Counts 101-400 Cells-/mm(3) and Plasma HIV RNA Less Than 50 Copies/mL After at Least 12 M of HAART
This study will evaluate the safety of a new experimental drug, IL-7, in people with HIV
infection. Animal studies have shown that IL-7 can improve the function and number of
infection-fighting cells called T lymphocytes, or T cells. If this study shows that IL-7 is
safe, additional studies will be done to see if it can improve the function or numbers of
T-cells in HIV-infected persons.
HIV-infected persons who have been receiving HAART therapy for at least 12 months before
enrolling in the study and have been stable on this treatment for at least 3 months before
enrollment may be eligible for this study.
Participants have about 10 clinic visits over 3 months. They receive three injections of
IL-7, one injection a week for 3 consecutive weeks. The injections are given as a shot under
the skin in the arm or leg. On the day of each injection, the participant stays in the
clinic for up to 8 hours or longer for observation and collection of blood samples. Three
additional visits (one every 3 months) may be scheduled.
During the study visits the following may be done:
- Medical history, physical examination, blood tests every visit.
- Electrocardiogram (EKG) at study days 0 (day of first dose), 1, 7 (day of second dose),
14 (day of third dose) and 21.
- Chest x-ray study on day 21.
- Blood sample collections at frequent intervals during the first 96 hours after the
first dose administration. A catheter (thin plastic tube) may be put into a vein in the
arm and left in place to allow several blood samples to be drawn without repeated
needle sticks.
- Urine tests several times during the study.
Interleukin 7 (IL-7) is an essential cytokine for the thymic development and the post-thymic
survival, expansion and maturation of T lymphocytes in humans. The rationale for using IL-7
as immunotherapy in HIV infection would be to support the expansion, survival and functional
properties of T lymphocytes and enhance immune reconstitution. Phase I studies of a previous
formulation of rhIL7 in cancer and HIV infected patients have shown that T cell
proliferation and expansion can be achieved at doses that are well tolerated. The newly
glycosylated form of IL-7 tested in this study has a longer half-life allowing weekly
administrations.
This is a phase I/IIa, open label, single arm trial that will test the safety of three
subcutaneous injections of IL-7 at three different dose levels (10, 20 and 30
micrograms/kilograms) that will be tested sequentially. Eligible subjects (400
cells/microliters greater than CD4 greater than 101 cells/microliters and VL less than 1000
copies/milliliter, on antiretroviral therapy for at least one year) will be given 3 doses of
IL-7 at weekly intervals (day 0, day 7 and day 14). Participants will be followed on days 0,
1, 4, 7, 14, 21 and 28 with additional visits on days 35, 56, and 77 and optional follow up
every 3 months thereafter until week 56 (approximately 1 year after enrollment). The three
doses will be tested sequentially (10, 20 and 30 micrograms/kilograms per dose) and dose
escalation will occur only when safety data from day 28 of the previous dose level
participants are complete.
Ten subjects will enroll in each dose level and dose escalation will occur only after all
subjects complete four weeks without evidence of dose-limiting toxicities. Secondary end
points include a PK study of glycosylated rhIL7 as well as immunologic studies throughout
the duration of the study to assess evidence of IL7 biologic activity with markers of T cell
proliferation and expression of the alpha chain of the IL7 receptor. This is a multi-center
international study sponsored by Cytheris with sites in USA, Canada, Italy and France.
Children will be excluded and a separate study will be required in the future after the
safety and biologic activity of this agent is established in adults. The study will enroll a
total of approximately 30 participants.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |